prostate-cancer

Documents about prostate-cancer

• Clinical impact of PSMA PET fusion-based RT planning on dosimetry and PSA response in prostate cancer#450225Recep Tayyip Erdoğan University Institutional Repository
• Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy#843161ClinicalTrials.gov
• Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance#834983ClinicalTrials.gov
• Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors#283053ClinicalTrials.gov
• Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer#28331ClinicalTrials.gov
• CARDIOVASCULAR RISK FACTORS AMONG NEWLY DIAGNOSED PROSTATE CANCER PATIENTS#222633Indonesian Journal of Urology
• SBRT for Localized Prostate Cancer: CyberKnife vs. VMAT-FFF, a Dosimetric Study#247036IRIS
• Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer#253005ClinicalTrials.gov
• Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate Brachytherapy#801121ClinicalTrials.gov
• Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC#807092ClinicalTrials.gov
• Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer Treatment#834494ClinicalTrials.gov
• Cancer statistics, 2013#6880OpenAlex
• A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies#804957ClinicalTrials.gov
• Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck Cancers#826618ClinicalTrials.gov
• Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer#834465ClinicalTrials.gov
• The Genetic Education for Men Trial: Web-Based Education vs. Standard Care#828286ClinicalTrials.gov
• Addressing Health Literacy With a Tailored Survivorship Care Plan#837744ClinicalTrials.gov
• Retrospective Evaluation of a Commercially Available Hydrogel Spacer (BP-009)#825694ClinicalTrials.gov
• Characterize Tumor Hypoxia by Magnetic Resonance Imaging#831700ClinicalTrials.gov
• Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy#148603ClinicalTrials.gov
• Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer#623505ClinicalTrials.gov
• Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer#683099ClinicalTrials.gov
• Understanding of Genetics by Men at Risk for Prostate Cancer#801337ClinicalTrials.gov
• Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer#825804ClinicalTrials.gov
• Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer#826216ClinicalTrials.gov
• PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer#831348ClinicalTrials.gov
• Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.#845808ClinicalTrials.gov
• A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)#813565ClinicalTrials.gov
• Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy#826734ClinicalTrials.gov
• Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer#800509ClinicalTrials.gov
• Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients#231810IRIS
• Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy#841242ClinicalTrials.gov
• Analysis of the Mechanisms of Actions of Heat Shock Protein (Hsp27) Responsible of the Androgen-independent Evolution in Prostate Cancer#148764ClinicalTrials.gov
• Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)#300254ClinicalTrials.gov
• Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients#398285ClinicalTrials.gov
• A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer#801591ClinicalTrials.gov
• Early Investigation of High Precision Radiotherapy Prior to Commencing Standard Radiotherapy for Prostate Cancer#803017ClinicalTrials.gov
• Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients#807309ClinicalTrials.gov
• HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer#808119ClinicalTrials.gov
• Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer#835201ClinicalTrials.gov
• HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer#846171ClinicalTrials.gov
• Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin#195535ClinicalTrials.gov
• Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer#125830ClinicalTrials.gov
• Pillars4Life Trial#806478ClinicalTrials.gov
• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations#387171ClinicalTrials.gov
• Cancer statistics, 2016#6843OpenAlex
• 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks#839420ClinicalTrials.gov
• Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer#67843ClinicalTrials.gov
• Overall and central obesity and prostate cancer risk in African men#197742University of Ibadan Institutional Repository
• Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions#326508IRIS